Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Viral Infections May Have Met Their Match

Published: Friday, November 29, 2013
Last Updated: Friday, November 29, 2013
Bookmark and Share
Researchers ID protein that sets off body's response to fight infection.

A Massachusetts General Hospital-led research team has identified an immune cell protein that is critical to setting off the body’s initial response against viral infection.

The report describes finding that a protein called GEF-H1 is essential to the ability of macrophages — major contributors to the innate immune system — to respond to viral infections such as influenza. The report will be published in an upcoming issue of Nature Immunology and is receiving early online release.

“The detection of viral genetic material inside an infected cell is critical to initiating the responses that signal the immune system to fight an infection and prevent its spread throughout the body,” said Hans-Christian Reinecker of the Center for the Study of Inflammatory Bowel Disease in the MGH Gastrointestinal Unit, senior author of the report. “Our findings indicate that GEF-H1 may control immune responses against a wide variety of RNA and DNA viruses that pose a threat to human health.”

The body’s first line of defense against infection, the innate immune system rapidly responds to invading pathogens by mobilizing white blood cells, chemical factors called cytokines, and antimicrobial peptides. When viruses invade cells, they often move toward the nucleus to replicate and sometimes to integrate their own genetic material into that of the host cell, traveling along structures called microtubules that cells use for internal protein transport. But how microtubule-based movement of viral components contributes to induction of the immune response has been unknown.

GEF-H1 is known to bind to microtubules, and previous research indicated that it has a role in immune recognition of bacteria. A series of experiments by Reinecker’s team found that GEF-H1 is expressed in macrophages — key components of the innate immune system — and activated in response to viral RNA, and that it controls the expression of beta interferon and other cytokines.  Mice in which expression of GEF-H1 was knocked out were unable to mount an effective immune response to influenza A and to encephalomyocarditis, a virus that causes several types of infection in animals.

“The sensing of intracellular viral nucleic acids for induction of interferons is so important that many viruses, including influenza A, have evolved specific strategies to interfere with activation of the interferon defense system,” said Reinecker, an associate professor of medicine at Harvard Medical School. “We are hopeful that this discovery will allow the development of new strategies to curtail viral mechanisms that impede the immune responses to infections that are often associated with high mortality rates.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Escape Prevention
Studying flu virus structure brings us a step closer to a permanent vaccine.
Monday, October 05, 2015
Asthma Cells Scramble Like ‘There’s a Fire Drill’
Movement offers insight into mechanisms of asthma, other diseases.
Friday, August 14, 2015
Giant Leap Against Diabetes
Ability to produce embryonic stem cells will allow researchers to push faster toward cure.
Friday, October 10, 2014
Airway Muscle-On-A-Chip Mimics Asthma
Tissue-level model of human airway musculature could pave way for patient-specific asthma treatments.
Wednesday, September 24, 2014
Cancer Vaccine Begins Phase I Clinical Trials
Cross-disciplinary team brings novel therapeutic cancer vaccine to human clinical trials.
Wednesday, September 11, 2013
Scientific News
Developing Drug Resistance may be a Matter of Diversity for Tuberculosis
Researchers have probed the bacteria that causes tuberculosis, Mycobacterium tuberculosis, to learn more about how individual bacterial cells change and adapt while in the human body.
Surprising Trait Found in Anti-HIV Antibodies
Scientists at The Scripps Research Institute (TSRI) have new weapons in the fight against HIV.
Some Gut Microbes May Be Keystones of Health
University of Oregon scientists have found that strength in numbers doesn’t hold true for microbes in the intestines. A minority population of the right type might hold the key to regulating good health.
Essential Component of Antiviral Defense Identified
Infectious disease researchers at the University of Georgia have identified a signaling protein critical for host defense against influenza infection.
Single Vaccine for Chikungunya, Related Viruses May be Possible
What if a single vaccine could protect people from infection by many different viruses? That concept is a step closer to reality.
Is Allergy the Price We Pay for Our Immunity to Parasites?
New findings help demonstrate the evolutionary basis for allergy.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
Mucus – the First Line of Defence
Researchers reveal the important role of mucus in building a good defence against invaders.
Antibody Targets Key Cancer Marker
University of Wisconsin-Madison researchers have created a molecular structure that attaches to a molecule on highly aggressive brain cancer and causes tumors to light up in a scanning machine.
Gene-Edited Immune Cells Treat ‘Incurable’ Leukaemia
A new treatment that uses ‘molecular scissors’ to edit genes and create designer immune cells programmed to hunt out and kill drug resistant leukaemia has been used at Great Ormond Street Hospital (GOSH).

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos